Heparin cofactor II, a serine protease inhibitor, promotes angiogenesis via activation of the AMP-activated protein kinase-endothelial nitric-oxide synthase signaling pathway

Journal of Biological Chemistry

Volumn 287, Issue 41, 2012, Pages 34256-34263

  Ikeda, Yasumasa ^a   Aihara, Ken Ichi ^a   Yoshida, Sumiko ^a   Iwase, Takashi ^a   Tajima, Soichiro ^a   Izawa Ishizawa, Yuki ^a   Kihira, Yoshitaka ^a   Ishizawa, Keisuke ^a   Tomita, Shuhei ^a   Tsuchiya, Koichiro ^a   Sata, Masataka ^a   Akaike, Masashi ^a   Kato, Shigeaki ^b   Matsumoto, Toshio ^a   Tamaki, Toshiaki ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMP-ACTIVATED PROTEIN KINASE; ANGIOGENESIS; BLOOD FLOW; CAPILLARY DENSITY; CAPILLARY NUMBERS; CARDIO-VASCULAR DISEASE; CLINICAL STUDY; ENDOTHELIAL NITRIC-OXIDE SYNTHASE (ENOS); HEPARIN COFACTOR II; HIND LIMBS; HUMAN AORTIC ENDOTHELIAL CELLS; LASER SPECKLE; NITRIC-OXIDE SYNTHASE; PRE-TREATMENT; PROTECTIVE ACTION; SERINE PROTEASE INHIBITOR; SERINE PROTEINASE INHIBITORS; SIGNALING PATHWAYS; THERAPEUTIC TARGETS; TUBE FORMATION; VASCULAR ENDOTHELIAL CELLS; WILD TYPES;

ACTIVATION ANALYSIS; AMINO ACIDS; ENDOTHELIAL CELLS; HEMODYNAMICS; MUSCLE; PHOSPHORYLATION; POLYSACCHARIDES;

MAMMALS;

ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEPARIN COFACTOR II; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIVER ENZYME; LIVER KINASE B1; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; BLOOD FLOW; CAPILLARY DENSITY; CELL ACTIVATION; CELL LEVEL; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CONVALESCENCE; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; HEART PROTECTION; HINDLIMB; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRACELLULAR SIGNALING; LIMB ISCHEMIA; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; AORTA; CELL MOVEMENT; ENDOTHELIAL CELLS; HEPARIN COFACTOR II; HUMANS; MALE; MICE; MICE, MUTANT STRAINS; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; SIGNAL TRANSDUCTION;

EID: 84867280833     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.353532     Document Type: Article

References (43)

1. Tollefsen, D. M., Majerus, D. W., and Blank, M. K. (1982) Heparin cofactor II: purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J. Biol. Chem. 257, 2162-2169 (Pubitemid 12069768)
2. Tollefsen, D. M., Pestka, C. A., and Monafo, W. J. (1983) Activation of heparin cofactor II by dermatan sulfate. J. Biol. Chem. 258, 6713-6716 (Pubitemid 13059936)
3. Derian, C. K., Damiano, B. P., D'Andrea, M. R., and Andrade-Gordon, P. (2002) Thrombin regulation of cell function through protease-activated receptors: implications for therapeutic intervention. Biochemistry 67, 56-64
4. Parker, K. A., and Tollefsen, D. M. (1985) The protease specificity of heparin cofactor II: inhibition of thrombin generated during coagulation. J. Biol. Chem. 260, 3501-3505 (Pubitemid 15114349)
5. Tollefsen, D. M. (2007) Heparin cofactor II modulates the response to vascular injury. Arterioscler. Thromb. Vasc. Biol. 27, 454-460
6. Shirk, R. A., Parthasarathy, N., San Antonio, J. D., Church, F. C., and Wagner, W. D. (2000) Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque. J. Biol. Chem. 275, 18085-18092 (Pubitemid 30414757)
7. Kanagawa, Y., Shigekiyo, T., Aihara, K., Akaike, M., Azuma, H., and Matsumoto, T. (2001) Molecular mechanism of type I congenital heparin cofactor (HC) II deficiency caused by a missense mutation at reactive P2 site: HC II Tokushima. Thromb. Haemost. 85, 101-107 (Pubitemid 32050950)
8. Aihara, K., Azuma, H., Takamori, N., Kanagawa, Y., Akaike, M., Fujimura, M., Yoshida, T., Hashizume, S., Kato, M., Yamaguchi, H., Kato, S., Ikeda, Y., Arase, T., Kondo, A., and Matsumoto, T. (2004) Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Circulation 109, 2761-2765 (Pubitemid 38744553)
9. Takamori, N., Azuma, H., Kato, M., Hashizume, S., Aihara, K., Akaike, M., Tamura, K., and Matsumoto, T. (2004) High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Circulation 109, 481-486 (Pubitemid 38168510)
10. Schillinger, M., Exner, M., Sabeti, S., Mlekusch, W., Amighi, J., Handler, S., Quehenberger, P., Kalifeh, N., Wagner, O., and Minar, E. (2004) High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stenting. Thromb. Haemost. 92, 1108-1113 (Pubitemid 39545536)
11. Vicente, C. P., He, L., and Tollefsen, D. M. (2007) Accelerated atherogenesis and neointima formation in heparin cofactor II-deficient mice. Blood 110, 4261-4267 (Pubitemid 351377790)
12. Aihara, K., Azuma, H., Akaike, M., Ikeda, Y., Sata, M., Takamori, N., Yagi, S., Iwase, T., Sumitomo, Y., Kawano, H., Yamada, T., Fukuda, T., Matsumoto, T., Sekine, K., Sato, T., Nakamichi, Y., Yamamoto, Y., Yoshimura, K., Watanabe, T., Nakamura, T., Oomizu, A., Tsukada, M., Hayashi, H., Sudo, T., and Kato, S. (2007) Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice. J. Clin. Invest. 117, 1514-1526 (Pubitemid 46871336)
13. Ise, T., Aihara, K., Sumitomo-Ueda, Y., Yoshida, S., Ikeda, Y., Yagi, S., Iwase, T., Yamada, H., Akaike, M., Sata, M., and Matsumoto, T. (2011) Plasma heparin cofactor II activity is inversely associated with left atrial volume and diastolic dysfunction in humans with cardiovascular risk factors. Hypertens. Res. 34, 225-231
14. Sumitomo-Ueda, Y., Aihara, K., Ise, T., Yoshida, S., Ikeda, Y., Uemoto, R., Yagi, S., Iwase, T., Ishikawa, K., Hirata, Y., Akaike, M., Sata, M., Kato, S., and Matsumoto, T. (2010) Heparin cofactor II protects against angiotensin II-induced cardiac remodeling via attenuation of oxidative stress in mice. Hypertension 56, 430-436
15. Murohara, T., Asahara, T., Silver, M., Bauters, C., Masuda, H., Kalka, C., Kearney, M., Chen, D., Symes, J. F., Fishman, M. C., Huang, P. L., and Isner, J. M. (1998) Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J. Clin. Invest. 101, 2567-2578 (Pubitemid 28270451)
16. Aihara, K., Azuma, H., Akaike, M., Kurobe, H., Takamori, N., Ikeda, Y., Sumitomo, Y., Yoshida, S., Yagi, S., Iwase, T., Ishikawa, K., Sata, M., Kitagawa, T., and Matsumoto, T. (2009) Heparin cofactor II is an independent protective factor against peripheral arterial disease in elderly subjects with cardiovascular risk factors. J. Atheroscler. Thromb. 16, 127-134
17. Ikeda, Y., Tajima, S., Yoshida, S., Yamano, N., Kihira, Y., Ishizawa, K., Aihara, K., Tomita, S., Tsuchiya, K., and Tamaki, T. (2011) Deferoxamine promotes angiogenesis via the activation of vascular endothelial cell function. Atherosclerosis 215, 339-347
18. Ikeda, Y., Ohashi, K., Shibata, R., Pimentel, D. R., Kihara, S., Ouchi, N., and Walsh, K. (2008) Cyclooxygenase-2 induction by adiponectin is regulated by a sphingosine kinase-1-dependent mechanism in cardiac myocytes. FEBS Lett. 582, 1147-1150
19. Ikeda, Y., Aihara, K., Sato, T., Akaike, M., Yoshizumi, M., Suzaki, Y., Izawa, Y., Fujimura, M., Hashizume, S., Kato, M., Yagi, S., Tamaki, T., Kawano, H., Matsumoto, T., Azuma, H., and Kato, S. (2005) Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. J. Biol. Chem. 280, 29661-29666 (Pubitemid 41177042)
20. Yamanaga, K., Yuuki, T., Tsukada, M., Koshiba, H., Nakajima, T., Takechi, K., and Nakamura, N. (2000) Heparin cofactor II inhibits thrombus formation in a rat thrombosis model. Thromb. Res. 98, 95-101 (Pubitemid 30114264)
21. Ikeda, Y., Aihara, K., Akaike, M., Sato, T., Ishikawa, K., Ise, T., Yagi, S., Iwase, T., Ueda, Y., Yoshida, S., Azuma, H., Walsh, K., Tamaki, T., Kato, S., and Matsumoto, T. (2010) Androgen receptor counteracts doxorubicin-induced cardiotoxicity in male mice. Mol. Endocrinol. 24, 1338-1348
22. Chen, Z. P., Mitchelhill, K. I., Michell, B. J., Stapleton, D., Rodriguez-Crespo, I., Witters, L. A., Power, D. A., Ortiz de Montellano, P. R., and Kemp, B. E. (1999) AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 443, 285-289 (Pubitemid 29080812)
23. Morrow, V. A., Foufelle, F., Connell, J. M., Petrie, J. R., Gould, G. W., and Salt, I. P. (2003) Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J. Biol. Chem. 278, 31629-31639 (Pubitemid 37048341)
24. Ohashi, K., Ouchi, N., Higuchi, A., Shaw, R. J., and Walsh, K. (2010) LKB1 deficiency in Tie2-Cre-expressing cells impairs ischemia-induced angiogenesis. J. Biol. Chem. 285, 22291-22298
25. 1177 via an AMPK-mediated pathway independent of PI3K-Akt. FEBS Lett. 573, 175-180
26. 2+/calmodulin-dependent protein kinase β. Mol. Cell. Biol. 26, 5933-5945
27. Eto, M., Barandiér, C., Rathgeb, L., Kozai, T., Joch, H., Yang, Z., and Lüscher, T. F. (2001) Thrombin suppresses endothelial nitric-oxide synthase and up-regulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ. Res. 89, 583-590 (Pubitemid 32924212)
28. 495 phosphorylation. Exp. Biol. Med. 234, 132-139
29. Ohkawara, H., Ishibashi, T., Saitoh, S., Inoue, N., Sugimoto, K., Kamioka, M., Uekita, H., Kaneshiro, T., Ando, K., Takuwa, Y., Maruyama, Y., and Takeishi, Y. (2010) Preventive effects of pravastatin on thrombin-triggered vascular responses via Akt/eNOS and RhoA/Rac1 pathways in vivo. Cardiovasc. Res. 88, 492-501
30. Brevetti, G., Schiano, V., and Chiariello, M. (2008) Endothelial dysfunction: a key to the pathophysiology and natural history of peripheral arterial disease? Atherosclerosis 197, 1-11
31. Mees, B., Wagner, S., Ninci, E., Tribulova, S., Martin, S., van Haperen, R., Kostin, S., Heil, M., de Crom, R., and Schaper, W. (2007) Endothelial nitric-oxide synthase activity is essential for vasodilation during blood flow recovery but not for arteriogenesis. Arterioscler. Thromb. Vasc. Biol. 27, 1926-1933 (Pubitemid 47312300)
32. Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., and Zeiher, A. M. (1999) Activation of nitric-oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399, 601-605
33. Chen, H., Montagnani, M., Funahashi, T., Shimomura, I., and Quon, M. J. (2003) Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem. 278, 45021-45026 (Pubitemid 37377262)
34. Harris, M. B., Blackstone, M. A., Sood, S. G., Li, C., Goolsby, J. M., Venema, V. J., Kemp, B. E., and Venema, R. C. (2004) Acute activation and phosphorylation of endothelial nitric-oxide synthase by HMG-CoA reductase inhibitors. Am. J. Physiol. Heart Circ. Physiol. 287, H560-566 (Pubitemid 38955284)
35. Levine, Y. C., Li, G. K., and Michel, T. (2007) Agonist-modulated regulation of AMP-activated protein kinase (AMPK) in endothelial cells: evidence for an AMPK → Rac1 → Akt → endothelial nitric-oxide synthase pathway. J. Biol. Chem. 282, 20351-20364 (Pubitemid 47100039)
36. Izumi, Y., Shiota, M., Kusakabe, H., Hikita, Y., Nakao, T., Nakamura, Y., Muro, T., Miura, K., Yoshiyama, M., and Iwao, H. (2009) Pravastatin accelerates ischemia-induced angiogenesis through AMP-activated protein kinase. Hypertens. Res. 32, 675-679
37. Li, P., Shibata, R., Maruyama, S., Kondo, M., Ohashi, K., Ouchi, N., and Murohara, T. (2010) Fenofibrate promotes ischemia-induced revascularization through the adiponectin-dependent pathway. Am. J. Physiol. Endocrinol. Metab. 299, E560-566
38. Kondo, M., Shibata, R., Miura, R., Shimano, M., Kondo, K., Li, P., Ohashi, T., Kihara, S., Maeda, N., Walsh, K., Ouchi, N., and Murohara, T. (2009) Caloric restriction stimulates revascularization in response to ischemia via adiponectin-mediated activation of endothelial nitric-oxide synthase. J. Biol. Chem. 284, 1718-1724
39. 633. Circ. Res. 104, 496-505
40. Huang, P. H., Leu, H. B., Chen, J. W., Wu, T. C., Lu, T. M., Yu-An Ding, P., and Lin, S. J. (2007) Decreased heparin cofactor II activity is associated with impaired endothelial function determined by brachial ultrasonography and predicts cardiovascular events. Int. J. Cardiol. 114, 152-158 (Pubitemid 44791503)
41. Hawley, S. A., Boudeau, J., Reid, J. L., Mustard, K. J., Udd, L., Mäkelä, T. P., Alessi, D. R., and Hardie, D. G. (2003) Complexes between the LKB1 tumor suppressor, STRAD α/β and MO25 α/β are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2, 28
42. Ouchi, N., Shibata, R., and Walsh, K. (2005) AMP-activated protein kinase signaling stimulates VEGF expression and angiogenesis in skeletal muscle. Circ. Res. 96, 838-846 (Pubitemid 40604967)
43. Minami, T., Sugiyama, A., Wu, S. Q., Abid, R., Kodama, T., and Aird, W. C. (2004) Thrombin and phenotypic modulation of the endothelium. Arterioscler. Thromb. Vasc. Biol. 24, 41-53 (Pubitemid 38082410)